Estimating global treatment toxicity burden from adverse-event data.

about

Estimating global treatment toxicity burden from adverse-event data.

Item

http://www.wikidata.org/entity/Q47641160

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Estimating global treatment toxicity burden from adverse-event data.

@en

Estimating global treatment toxicity burden from adverse-event data.

@nl

type

Item

label

Estimating global treatment toxicity burden from adverse-event data.

@en

Estimating global treatment toxicity burden from adverse-event data.

@nl

prefLabel

Estimating global treatment toxicity burden from adverse-event data.

@en

Estimating global treatment toxicity burden from adverse-event data.

@nl

P1476

Estimating global treatment toxicity burden from adverse-event data.

@en

P2093

Jieling Miao

http://www.w3.org/2001/XMLSchema#string

Joseph M Unger

http://www.w3.org/2001/XMLSchema#string

Shing M Lee

http://www.w3.org/2001/XMLSchema#string

Xiaobo Zhong

http://www.w3.org/2001/XMLSchema#string

Ying Kuen Ken Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Fitting Linear Mixed-Effects Models Usinglme4

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

Toxicity burden score: a novel approach to summarize multiple toxic effects.

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

P31

scholarly article

P356

10.1002/CNCR.31107

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Dawn L Hershman

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29112232

http://www.w3.org/2001/XMLSchema#string

P932

5801103

http://www.w3.org/2001/XMLSchema#string